Circulating ketone bodies and cardiovascular outcomes: the MESA study.

AIMS Ketone bodies (KB) are an important alternative metabolic fuel source for the myocardium. Experimental and human investigations suggest that KB may have protective effects in patients with heart failure. This study aimed to examine the association between KB and cardiovascular outcomes and mortality in an ethnically diverse population free from cardiovascular disease (CVD). METHODS AND RESULTS This analysis included 6796 participants (mean age 62 ± 10 years, 53% women) from the Multi-Ethnic Study of Atherosclerosis. Total KB was measured by nuclear magnetic resonance spectroscopy. Multivariable-adjusted Cox proportional hazard models were used to examine the association of total KB with cardiovascular outcomes. At a mean follow-up of 13.6 years, after adjusting for traditional CVD risk factors, increasing total KB was associated with a higher rate of hard CVD, defined as a composite of myocardial infarction, resuscitated cardiac arrest, stroke, and cardiovascular death, and all CVD (additionally included adjudicated angina) [hazard ratio, HR (95% confidence interval, CI): 1.54 (1.12-2.12) and 1.37 (1.04-1.80) per 10-fold increase in total KB, respectively]. Participants also experienced an 87% (95% CI: 1.17-2.97) increased rate of CVD mortality and an 81% (1.45-2.23) increased rate of all-cause mortality per 10-fold increase in total KB. Moreover, a higher rate of incident heart failure was observed with increasing total KB [1.68 (1.07-2.65), per 10-fold increase in total KB]. CONCLUSION The study found that elevated endogenous KB in a healthy community-based population is associated with a higher rate of CVD and mortality. Ketone bodies could serve as a potential biomarker for cardiovascular risk assessment.

[1]  Svati H Shah,et al.  Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF , 2022, Circulation.

[2]  M. Connelly,et al.  Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. , 2021, Journal of the American College of Cardiology.

[3]  P. Magni,et al.  Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting , 2021, Nutrients.

[4]  M. Connelly,et al.  Association of beta‐hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort , 2020, European journal of clinical investigation.

[5]  M. Laakso,et al.  Novel biomarkers associated with incident heart failure in 10 106 Finnish men , 2020, ESC heart failure.

[6]  P. Ponikowski,et al.  Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status , 2020, Circulation.

[7]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[8]  S. Selvaraj,et al.  Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure , 2020, Circulation.

[9]  K. Clarke,et al.  Cardiac ketone body metabolism. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[10]  Sheng-Shou Hu,et al.  Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy , 2020, Science Translational Medicine.

[11]  M. Budoff,et al.  N-terminal Pro B-type Natriuretic Peptide and High-sensitivity Cardiac Troponin as Markers for Heart Failure and Cardiovascular Disease Risks According to Glucose Status (from the Multi-Ethnic Study of Atherosclerosis [MESA]). , 2020, The American journal of cardiology.

[12]  M. Connelly,et al.  Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index , 2020, Journal of clinical medicine.

[13]  R. de Cabo,et al.  Effects of Intermittent Fasting on Health, Aging, and Disease. , 2019, The New England journal of medicine.

[14]  Rick B. Vega,et al.  The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. , 2019, JCI insight.

[15]  H. Bøtker,et al.  Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients , 2019, Circulation.

[16]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[17]  Hiroaki Sunaga,et al.  Association Between Circulating Ketone Bodies and Worse Outcomes in Hemodialysis Patients , 2017, Journal of the American Heart Association.

[18]  H. Bøtker,et al.  Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study , 2017, Journal of the American Heart Association.

[19]  P. Puchalska,et al.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.

[20]  A. Pereira,et al.  Impact of Exhaled Breath Acetone in the Prognosis of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). One Year of Clinical Follow-up , 2016, PloS one.

[21]  Steffen E. Petersen,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2016, European journal of preventive cardiology.

[22]  J. McMurray,et al.  SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? , 2016, Diabetologia.

[23]  Y. Takeishi,et al.  Exhaled Acetone Concentration Is Related to Hemodynamic Severity in Patients With Non-Ischemic Chronic Heart Failure. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[24]  Rick B. Vega,et al.  The Failing Heart Relies on Ketone Bodies as a Fuel , 2016, Circulation.

[25]  K. Margulies,et al.  Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure , 2016, Circulation.

[26]  R. Tian,et al.  Ketones Step to the Plate: A Game Changer for Metabolic Remodeling in Heart Failure? , 2016, Circulation.

[27]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[28]  Yuli Huang,et al.  1H-NMR-Based Metabolic Analysis of Human Serum Reveals Novel Markers of Myocardial Energy Expenditure in Heart Failure Patients , 2014, PloS one.

[29]  Eric Verdin,et al.  Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor , 2013, Science.

[30]  E. Bocchi,et al.  Exhaled acetone as a new biomaker of heart failure severity. , 2012, Chest.

[31]  Tuija Tammelin,et al.  Metabolic Signatures of Insulin Resistance in 7,098 Young Adults , 2012, Diabetes.

[32]  W. Kraus,et al.  Metabolic profiles predict adverse events after coronary artery bypass grafting. , 2012, The Journal of thoracic and cardiovascular surgery.

[33]  D. Levy,et al.  Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. , 2011, The Journal of clinical endocrinology and metabolism.

[34]  Eric Boerwinkle,et al.  Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.

[35]  J. Polak,et al.  Dietary patterns and incident cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. , 2009, The American journal of clinical nutrition.

[36]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[37]  Masato Kasuga,et al.  [Obesity and insulin resistance]. , 2009, Nihon rinsho. Japanese journal of clinical medicine.

[38]  Moyses Szklo,et al.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.

[39]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[40]  A. Srivastava,et al.  Chronic exposure to beta-hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes. , 2001, American journal of physiology. Endocrinology and metabolism.

[41]  J. Levy,et al.  Within- and between-subject variation in commonly measured anthropometric and biochemical variables. , 1999, Clinical chemistry.

[42]  B. Singh,et al.  Insulin resistance in the regulation of lipolysis and ketone body metabolism in non-insulin dependent diabetes is apparent at very low insulin concentrations. , 1993, Diabetes research and clinical practice.